TipRanks
Elicio Therapeutics (DE:9HA)
FRANKFURT:9HA
Germany Market
9HA
Elicio Therapeutics
RESEARCH TOOLSreports

Elicio Therapeutics (9HA) Income Statement

0 Followers

Elicio Therapeutics Income Statement

Last quarter (Q2 2026), Elicio Therapeutics's total revenue was $0.00, a decrease of ― from the same quarter last year. In Q2, Elicio Therapeutics's net income was $-8.22M. See Elicio Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 25Mar 25Dec 23Dec 22Dec 21
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 28.31M
Gross Profit
$ -1.13M$ -1.18M$ -1.17M$ -1.06M$ 27.08M
Operating Expenses
$ 36.59M$ 43.81M$ 34.58M$ 22.68M$ 66.39M
Depreciation and Amortization
$ 1.13M$ 1.18M$ 1.17M$ 1.06M$ 251.45K
EBITDA
$ -37.31M$ -50.27M$ -32.97M$ -23.55M$ -52.47M
Operating Income
$ -37.71M$ -44.99M$ -35.74M$ -23.73M$ -39.31M
Other Income/Expenses
$ -1.86M$ -6.91M$ 550.00K$ -4.47M$ -15.27M
Pretax Income
$ -39.57M$ -51.90M$ -35.20M$ -28.21M$ -54.57M
Net Income
$ -39.57M$ -51.90M$ -35.20M$ -28.21M$ -26.40M
Per Share Metrics
Basic EPS
$ -2.58$ -4.25$ -6.96$ -9.10$ -19.32
Diluted EPS
$ -2.58$ -4.25$ -6.96$ -9.10$ -19.32
Weighted Average Shares Outstanding
 15.31M 12.20M 5.06M 3.10M 3.20M
Weighted Average Shares Outstanding (Diluted)
 15.31M 12.20M 5.06M 3.10M 3.20M
Currency in USD

Elicio Therapeutics Earnings and Revenue History